Literature DB >> 11888087

Lung adenocarcinoma with bronchioloalveolar carcinoma component is frequently associated with foci of high-grade atypical adenomatous hyperplasia.

Takaomi Koga1, Shuichi Hashimoto, Kenji Sugio, Yoshikazu Yonemitsu, Yutaka Nakashima, Ichiro Yoshino, Yoshio Matsuo, Sepideh Mojtahedzadeh, Keizo Sugimachi, Katsuo Sueishi.   

Abstract

We assessed the occurrence of atypical adenomatous hyperplasia (AAH) in whole lung lobes with primary cancer lesions. Following surgical resection, tissue specimens were sliced to a thickness of 4 mm (3,641 specimens from 61 cases; mean = 59.7 specimens per case). A total of 119 AAH foci were found and an association was evident in 25 (57%) of 44 adenocarcinomas, 3 (30%) of 10 squamous cell carcinomas, and 2 (29%) of 7 other lung cancers. Histologic evaluation showed that 108 AAH foci were categorized as low-grade and the other 11 as high-grade AAH. These 11 foci of high-grade AAH were present in 7 patients with adenocarcinoma, and in 1 patient there was a synchronous double primary lung adenocarcinoma. High-grade AAH was closely associated with bronchioloalveolar carcinoma (BAC) type adenocarcinoma, and low-grade AAH with non-BAC adenocarcinoma. The mean +/- SD Ki-67 labeling index in high-grade AAH (3.5%+/-2.9%) was significantly higher than for the low-grade index (1.4%+/-1.6%). We propose that foci of high- but not low-grade AAH may be potential precursor lesions of lung adenocarcinoma, especially with the BAC component.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11888087     DOI: 10.1309/CHXA-3MH0-B7FD-JGUL

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  7 in total

Review 1.  Small peripheral lung adenocarcinoma: clinicopathological features and surgical treatment.

Authors:  Takayuki Fukui; Tetsuya Mitsudomi
Journal:  Surg Today       Date:  2010-02-24       Impact factor: 2.549

2.  Bronchioloalveolar neoplasia.

Authors:  Hitoshi Kitamura; Koji Okudela
Journal:  Int J Clin Exp Pathol       Date:  2010-11-12

Review 3.  International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.

Authors:  William D Travis; Elisabeth Brambilla; Masayuki Noguchi; Andrew G Nicholson; Kim R Geisinger; Yasushi Yatabe; David G Beer; Charles A Powell; Gregory J Riely; Paul E Van Schil; Kavita Garg; John H M Austin; Hisao Asamura; Valerie W Rusch; Fred R Hirsch; Giorgio Scagliotti; Tetsuya Mitsudomi; Rudolf M Huber; Yuichi Ishikawa; James Jett; Montserrat Sanchez-Cespedes; Jean-Paul Sculier; Takashi Takahashi; Masahiro Tsuboi; Johan Vansteenkiste; Ignacio Wistuba; Pan-Chyr Yang; Denise Aberle; Christian Brambilla; Douglas Flieder; Wilbur Franklin; Adi Gazdar; Michael Gould; Philip Hasleton; Douglas Henderson; Bruce Johnson; David Johnson; Keith Kerr; Keiko Kuriyama; Jin Soo Lee; Vincent A Miller; Iver Petersen; Victor Roggli; Rafael Rosell; Nagahiro Saijo; Erik Thunnissen; Ming Tsao; David Yankelewitz
Journal:  J Thorac Oncol       Date:  2011-02       Impact factor: 15.609

Review 4.  Glioblastoma and acute myeloid leukemia: malignancies with striking similarities.

Authors:  Eric Goethe; Bing Z Carter; Ganesh Rao; Naveen Pemmaraju
Journal:  J Neurooncol       Date:  2017-12-01       Impact factor: 4.130

Review 5.  C4.4A as a biomarker in pulmonary adenocarcinoma and squamous cell carcinoma.

Authors:  Benedikte Jacobsen; Mette Camilla Kriegbaum; Eric Santoni-Rugiu; Michael Ploug
Journal:  World J Clin Oncol       Date:  2014-10-10

Review 6.  [Overview of Clinical Progress in Pulmonary Ground-glass Nodules].

Authors:  Lei Li; Dan Liu; Yingying Zhu; Weimin Li
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2016-02

Review 7.  Rationale for Lung Adenocarcinoma Prevention and Drug Development Based on Molecular Biology During Carcinogenesis.

Authors:  Hongming Zhang; Liting Guo; Jibei Chen
Journal:  Onco Targets Ther       Date:  2020-04-14       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.